Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Whalewatcher1on Dec 27, 2021 7:30pm
75 Views
Post# 34264630

RE:Whalewatcher1 when you're going for the jugular don't miss!

RE:Whalewatcher1 when you're going for the jugular don't miss!Hi C10H12N2, maybe you understand this better. However I don't see how they qualify for the net income standard as they don't make any income and would need history of over $1M per year, see the requirements link below directly from Nasdaq. Even if they met that requirement they'd need to also have $15M US in stockholders equity, which they obviously don't have. It appears the Equity Standard is what they'd need to use, this requires $30M US in stock holders equity which they also don't have. Do you really think management even knows what they are doing here and setting up for an even greater failure. I'd assume they've already sent in application and have feedback before share consolidation, if feedback is contrary to what they've stated publicly they should provide market update. If you also look at cash balance, I don't nasdaq agrees with only monthly of cash left on runway

https://listingcenter.nasdaq.com/assets/initialguide.pdf

<< Previous
Bullboard Posts
Next >>